ADMA Biologics Announces First Commercial Sales of ASCENIV™
ADMA Biologics Inc (ADMA)
Last adma biologics inc earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.admabiologics.com
Company Research
Source: GlobeNewswire
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced the first commercial sales of ASCENIV (formerly known as RI-002). ASCENIV received approval from the U.S. Food and Drug Administration (“FDA”) on April 1, 2019. “The first commercial sales of ASCENIV, our third FDA-approved product, marks another major milestone in ADMA’s history,” said Adam Grossman, President and Chief Executive Officer of ADMA. “ASCENIV is a novel Intravenous Immune Globulin (“IVIG”), which is manufactured using our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested using ou
Show less
Read more
Impact Snapshot
Event Time:
ADMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADMA alerts
High impacting ADMA Biologics Inc news events
Weekly update
A roundup of the hottest topics
ADMA
News
- The Schall Law Firm Encourages Shareholders To Take Part In An Inquiry Into ADMA Biologics Inc For Securities Law Violations Accesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMAAccesswire
- ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm Accesswire
- The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations Accesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMAPR Newswire
ADMA
Earnings
- 11/7/24 - Beat
ADMA
Sec Filings
- 11/21/24 - Form 8-K
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- ADMA's page on the SEC website